Wouter Joustra Acquires enGene Therapeutics Shares

Wouter Joustra made a strategic move by purchasing 31,000 shares of enGene Therapeutics Inc. on June 16, 2026. This transaction did not have a reported value at the time, as it was coded as an acquisition without a specified purchase price.

enGene Therapeutics Stock Snapshot

Shares of NasdaqCM:ENGN traded at $1.75, with the company having a market capitalization of approximately $117.2 million. enGene Therapeutics is not currently profitable, showing no meaningful P/E ratio due to negative earnings per share of -$2.18. The stock has experienced a 52-week low of $1.40 and a high of $12.25. It has a 50-day moving average of $4.33 and a 200-day moving average of $7.13. The company's financial health appears strong with a current ratio of 12.57 and a quick ratio of 12.07, though it has a debt-to-equity ratio of 13.07.

About enGene Therapeutics Inc.

enGene Therapeutics Inc., headquartered in Montreal, Canada, is a clinical-stage biotechnology company. It focuses on developing genetic medicines to treat bladder cancer. The company's leading product is detalimogene voraplasmid, aimed at treating non-muscle invasive bladder cancer. enGene is also advancing its LEGEND pipeline, currently in Phase 2 trials. Led by CEO Ronald H. W. Cooper, enGene employs 81 people and continues to innovate in the healthcare sector.

Bottom Line

Wouter Joustra's recent purchase of enGene Therapeutics shares highlights ongoing interest in the biotech company's potential, especially as it advances its genetic medicine pipeline. Investors often track insider transactions like this for insights into company confidence. Remember, this transaction is disclosed after the fact and may not reflect current holdings.